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Abstract
Background: Attempts to reduce morbidity and mortality in breast cancer is based on efforts to identify novel
biomarkers to support prognosis and therapeutic choices. The present study has focussed on S100 proteins as a
potentially promising group of markers in cancer development and progression. One reason of interest in this
family of proteins is because the majority of the S100 genes are clustered on a region of human chromosome
1q21 that is prone to genomic rearrangements. Moreover, there is increasing evidence that S100 proteins are often
up-regulated in many cancers, including breast, and this is frequently associated with tumour progression.
Methods: Samples of breast cancer tissues were obtained during surgical intervention, according to the bioethical
recommendations, and cryo-preserved until used. Tissue extracts were submitted to proteomic preparations for
2D-IPG. Protein identification was performed by N-terminal sequencing and/or peptide mass finger printing.
Results: The majority of the detected S100 proteins were absent, or present at very low levels, in the non-tumoral
tissues adjacent to the primary tumor. This finding strengthens the role of S100 proteins as putative biomarkers.
The proteomic screening of 100 cryo-preserved breast cancer tissues showed that some proteins were ubiquitously
expressed in almost all patients while others appeared more sporadic. Most, if not all, of the detected S100
members appeared reciprocally correlated. Finally, from the perspective of biomarkers establishment, a promising
finding was the observation that patients which developed distant metastases after a three year follow-up showed
a general tendency of higher S100 protein expression, compared to the disease-free group.
Conclusions: This article reports for the first time the comparative proteomic screening of several S100 protein
members among a large group of breast cancer patients. The results obtained strongly support the hypothesis that
a significant deregulation of multiple S100 protein members is associated with breast cancer progression, and
suggest that these proteins might act as potential prognostic factors for patient stratification. We propose that this
may offer a significant contribution to the knowledge and clinical applications of the S100 protein family to breast
cancer.
Background
Breast cancer is still one of the most frequent forms of
cancer in women. Unfortunately, the biological and clin-
ical evolution of this type of cancer is not easily predict-
able since there are several types that behave differently
among patients. This biological heterogeneity is consis-
tent with observed varied responses to therapies across
patient populations. For this reason the search for new
biological markers to support prognosis and therapeutic
options remains an open field in oncology research.
One class of proteins that is emerging as a potentially
important group of markers in cancer development and
progression is the S100 family. S100 are small, acidic-
Ca
2+ binding proteins, found exclusively in vertebrates.
The first member was identified in the nervous system
by Moore in 1965 [1]. The S100 name is based on the
observation that they are soluble in 100% saturated
ammonium sulfate at neutral pH; at least 25 members
of the S100 protein family are recognized in human.
Twenty one of them (S100A1-S100A18, trichohylin, fil-
lagrin, repetin) are coded by genes clustered at
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entiation complex), while the other genes belonging to
the subfamilies of S100B, S100P, S100Z and S100G, are
respectively located at chromosome loci 21q22, 4p16,
5q14 and Xp22 [2]. S100 proteins form homo- and het-
erodimers, and even oligomers, and are expressed in tis-
sue and cell-specific manner, suggesting that each S100
protein may perform different functions [3]. Indeed, it is
well documented that S100 proteins are involved in sev-
eral biological processes, such as cell cycle regulation,
cell growth, cell differentiation and motility through a
broad range of intracellular and extracellular activities
[4-6]. Intracellular functions include regulation of pro-
tein calcium homeostasis, phosphorylation, regulation of
cytoskeletal components and regulation of transcrip-
tional factors. Extracellularly they act in a cytokine like
manner through the receptor for advanced glycation
end products (RAGE) [7].
The association between S100 family members and
tumors may be explained by several observations: firstly,
the region of human chromosome 1q21, where most of
S100 genes are clustered, is prone to genomic rearrange-
ments, likely supporting the tumor progression [8];
secondly, several S100 members show altered expression
levels in cancer cells compared to normal cells and are
differentially expressed in various malignancies, accord-
ing to types and stages of cancer [9-15]. Finally, a num-
ber of S100 proteins have been shown to interact with
and to regulate various proteins involved in cancer and
exert different effects on p53 activity [16-20]. However,
t h eo c c u r r e n c e ,t h er o l ea n dt h ep o s s i b l ec o o r d i n a t i o n
of this group of proteins in breast cancer is still poorly
known. In this study we describe a large-scale proteomic
investigation performed on breast cancer patients for the
screening of multiple forms of S100 proteins. The
results have shown that the majority of S100 proteins
were present at very low levels, if not absent, in the
non-tumoral tissues adjacent to the primary tumor. The
proteomic screening, extended to 100 cryo-preserved
breast cancer tissues, showed that some S100 protein
members were ubiquitously expressed in almost all
patients, while others appeared more sporadic among
the same group of patients. Most, if not all, of the
detected S100 members appeared reciprocally correlated.
More interestingly, patients which developed distant
metastases after a three year follow-up showed a general
tendency of higher S100 protein expression, compared
to the disease-free group.
Methods
Clinical specimens
The present study was conducted on 100 surgical tissues
of ductal infiltrating breast cancer collected between
2003 and 2007 in the Breast Unit of the La Maddalena
Hospital. Research was carried out in compliance with
the Helsinki Declaration with the patients’ written con-
sent and with the approval of the Institutional Review
Board (N°515/2008) from the La Maddalena Hospital.
The study used leftover specimens, that is, aliquots of
specimens collected for routine clinical care, and imme-
diately frozen at -80°C until used. The specimens were
not individually identifiable.
The patients of this study did not receive any cyto-
toxic/endocrine treatment prior to surgery. Diagnosis
of ductal breast cancer (G2/G3) was confirmed
histopathologically.
Post-operative monitoring to define whether or not dis-
tant metastases were present, was performed by conven-
tional imaging follow-up, consisting of chest radiography,
bone scintigraphy, magnetic resonance imaging (MRI)
and positron emission tomography using 2-[fluorine-18]
fluoro-2-deoxy-D-glucose (FDG-PET), as clinically indi-
cated at La Maddalena Hospital.
Sample preparations
The frozen breast tissue samples were washed several
times with phosphate-buffered saline and homogenized
in RIPA buffer (50 mM Tris pH 7.5, 0.1% Nonidet P-40,
0.1% deoxycholate, 150 mM NaCl, 4 mM EDTA) con-
taining a mixture of protease inhibitors (0.01% aprotinin,
10 mM sodium pyrophosphate, 2 mM sodium orthova-
nadate, 1 mM PMSF). The extraction was carried out
overnight at 4°C with the same buffer. The total cellular
lysate was centrifuged to remove tissue debris, and the
resulting supernatant dialysed against ultrapure distilled
water, lyophilized and stored at -80°C until use. The total
protein concentration was determined by the Bradford
method using bovine serum albumin as a standard [21].
Two Dimensional Gel Electrophoresis
The proteins extracted from breast cancer tissue and
normal adjacent tissue were solubilised in a buffer con-
taining 4% CHAPS, 40 mM Tris, 65 mM DTE in 8 M
urea. Aliquots of 45 μg (analytical gels) or 1.5 mg (pre-
parative gels) of total proteins were separately mixed
with 350 μL of rehydration solution containing 8 M
urea, 2% CHAPS, 10 mM DTE and 0.5% carrier anpho-
lytes (Resolyte 3.5-10), and applied for IEF using com-
mercial sigmoidal IPG strips, 18 cm long with pH range
3.0-10. The second dimension was carried out on 9-16%
linear gradient polyacrylamide gels (SDS-PAGE), and
the separated proteins were visualized by ammoniacal
silver staining. Stained gels were digitized using a com-
puting densitometer and analyzed with Image Master
software (Amersham Biosciences, Sweden). Gel calibra-
tion was carried out using an internal standard and the
support of the ExPaSy molecular biology server, as
described [22].
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N-Terminal microsequencing was performed by auto-
mated Edman degradation in a protein sequencer (Procise,
419 Applied Biosystems), as previously described [23].
Mass spectrometric sequencing was performed by
Voyager DE-PRO (Applied Biosystems) mass spectro-
meter as described [24]. Briefly, proteins were digested
using sequencing-grade trypsin (20 μg/vial). The tryptic
peptide extracts were dried and redissolved in 10 μLo f
0.1% trifluoroacetic acid (TFA). The matrix, R-cyano-
4-hydroxycinnamic acid (HCCA), was purchased from
Sigma-Aldrich. A saturated solution of HCCA (1 μL) at
2 mg/200 μL in CH3CN/H2O (50:50 (v/v)) containing
0.1% TFA was mixed with 1 μL of peptide solution on
the MALDI plate and left to dry. MALDI-TOF mass
spectra were recorded in the 500-5000 Da mass range,
using a minimum of 100 shots of laser per spectrum.
Delayed extraction source and reflector equipment
allowed sufficient resolution to consider MH+ of mono-
isotopic peptide masses. Internal calibration was done
using trypsin autolysis fragments at m/z 842.5100,
1045.5642, and 2211.1046 Da. Peptide mass fingerprint-
ing was compared to the theoretical masses from the
Swiss-Prot or NCBI sequence databases using Mascot
http://www.matrixscience.com/. Typical search para-
meters were as follows: (50 ppm of mass tolerance, car-
bamidomethylation of cysteine residues, one missed
enzymatic cleavage for trypsin, a minimum of four pep-
tide mass hits was required for a match, methionine
residues could be considered in oxidized form.
Western Blotting
For immune detection the 1D-gels were electrotrans-
ferred onto nitrocellulose membrane (HyBond ECL,
Amersham) and stained with Ponceau S (Sigma). The
membranes were then probed with one of the following
monoclonal antibodies: anti-actin (Oncogene), anti-
S100A2, anti-S100A4, anti-S100A6, anti-S100A7, anti
S100A8 (Santa Cruz), or polyclonal antibodies: anti-
S100A11, anti-S100A13 (SantaCruz). Following incuba-
tion with the appropriate peroxidase-linked antibody,
the reaction was revealed by the ECL detection system,
using high performance films (Hyperfilm ECL,
Amersham).
Quantification and normalization methods
Quantitative expression levels were calculated as the
volume of the spots (i.e. integration of optical density
over the spot area). In order to correct for differences in
gel staining, spot volumes relative to the sum of the
volume of all spots an each gel (%Vol) were calculated
by the software.
Since the cell densities within an area of the surgical
sample, may be very variable among the different
patients, measurements of relative expression levels of
individual protein spots were normalized in each map
for actin content [24] and the final value was designated
as N%V. The relative abundance of silver stained actin
was validated by western blot assays on the same tissue
extract (Fig. 1).
For statistical analyses Ms Excel and Graph Pad Prism
4 software were used. Correlation of S100 protein mem-
bers for breast cancer patients was performed using the
Pearson correlation test. The difference in S100 expres-
sion between metastatic versus disease free patients was
analyzed by unpaired F test. In all cases, p < 0.05 was
considered significant (*), p < 0.01 highly significant (**)
and p < 0.001 very highly significant (***).
Results
Proteomic identification of S100 proteins
In a previous work we reported the comparative pro-
teomic profiles of proteins from 37 breast cancer sur-
gical tissues [24]. Fig. 2 shows an updated proteomic
map representative of a breast surgical tissue. The
identified proteins are marked with labels correspond-
ing to the access number of the Swiss-Prot database:
Figure 1 Representative group of tissue extracts proteomics
assayed for the actin content. A) Experimental windows cropped
from Image-Master 2 D Platinum software containing the sections
of actin spots from the silver stained 2D-IPG. B) 1D-western blot
validation of the actin content on corresponding tissue extracts
with the same gel-loading.
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teins, were identified in the maps. The protein identity
was assessed by Maldi-Tof or N-Terminal
microsequencing.
Fig. 3A shows the image of a gel window comprising
an area covering a pI/kDa range of 4.5-7/15-9 kDa,
where the majority of known members of S100 proteins
are expected to localize.
After a comprehensive screening of protein spots
included in this area, in different proteomic maps, we
identified the following S100 protein members: S100A2
(protein S-100L), S100A4 (metastasin), S100A6 (Calcy-
clin, Prolactin receptor-associated protein), two iso-
forms, S100A7 (psoriasin), two isoforms, S100A8
(Calgranulin-A), S100A11 (Calgizzarin), three isoforms
and S100A13 (S100 calcium-binding protein A13). Dif-
ferent isoforms of the same protein were labelled by
alphabetic letters starting from the more acidic one.
Fig. 3B illustrates the Maldi-Tof mass spectra of the cor-
responding spots shown in Fig. 3A. The list of identified
proteins is shown in Table 1.
S100 proteins are preferentially expressed in the tumor mass
A group of 10 breast cancer tissues and their matched
non tumoral counterparts were analyzed for comparative
proteomic expression of the S100 proteins. Fig. 4 shows a
panel of the cropped images from 2-D matched gels of
the 10 selected patients. The S100 proteins are almost
exclusively present in the tumor extracts, even though
some S100 members are expressed at low, or very low
levels, for example S100A2, S100A4 and S100A8. Fig 5
shows box-plot graphs illustrating the quantitative varia-
tion of S100 protein expression levels between breast
cancer and normal adjacent tissues. Significant differ-
ences were observed for all S100 protein members,
except for S100A4 (expressed only in 5 patients) and for
S100A6 (expressed also in normal tissues). Therefore
these two proteins were not included in Fig. 5.
Proteomic distribution of S100 proteins within a cohort
of 100 breast cancer patients
Fig. 6A shows a diagram illustrating the occurrence of
the identified S100 protein members (abscissa) among
Figure 2 Representative gel image of a breast cancer tissue. 2-D separation was performed on IPG gel strips (18 cm, 3.0-10 NL) followed by
the SDS-PAGE on a vertical linear-gradient slab gel (9-16%T). Protein spots of known identity are marked with the Swiss-prot accession number.
When present, different isoforms of the same protein were jointly labelled.
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Page 4 of 12Figure 3 Identification of S100 proteins. A) Gel window comprising an area covering a pI/kDa range of 4.5-7/15-9 kDa, where the majority of
known members of non-keratin associated S100 proteins, are expected to localize. The protein spots localizing in this area were picked from the
gels and digested with trypsin. The resulting fragments were analyzed by mass spectrometry. Eleven spots were identified as S100 protein
members. The numbers indicate the eleven spots corresponding to S100 proteins, whose spectra are shown in B). The mass peaks marked with
an asterisk match the theoretical spectrum of the assigned proteins.
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The gray boxes indicate the absence of proteins in the
map of the corresponding patient and the crosses indi-
cate the patient expressing the given protein at its high-
est level. Interestingly, some proteins are expressed in
almost all patients (S100A6, S100A11, S100A2 and
S100A13); while others are expressed in a variable num-
ber of patients, i.e.: S100A8 in 71% of the patients,
S100A4 in 57% and S100A7 in 51% (isoform a) and 63%
(isoform b) (Fig. 6B).
In order to quantify the relative expression levels of
individual S100 protein members the intensity of each
protein spot was normalized for the actin content of the
corresponding map. Fig. 7 shows the expression levels
of each S100 protein, including isoforms, within the
cohort of 100 patients. Except for S100A6, the average
value of expression for each protein form (evaluated as
N%V) does not exceed the relative abundance value of
0.25. The expression range of each S100 member is
quite variable among patients: for instance, while the
basic form of S100A6 ranges from 0.009 to 1.7, S100A4
ranges from 0.005 to 0.35.
Relationship between expression levels of S100 members
The expression level of each S100 protein was cross-
tabulated with the other protein members and statistical
significance was assessed by the Pearson test. A signifi-
cant association was observed for a high percentage of
them (Fig. 8). More analytically, for S100 protein spots
present as multiple isoforms, the more basic ones, hav-
ing the closest pI to the theoretical values and likely
representing the primary gene product, showed positive
correlations with the other S100 members, except for
S100A7 b and S100A8 that showed no correlation with
the b-isoform of the S100A6 and with the S100A13.
Western blot validation of S100 proteins
Immunological assays were performed to confirm the
differential expression of all the S100 proteins identified
in 2D-IPG. Validation with the appropriate antibodies,
was performed on patient couples, chosen among the
ones indicated by P01-P100 in the diagram in Fig. 5A,
having high and low levels of the S100 proteins, respec-
tively. Fig. 9 shows a panel of cropped 2 D gels contain-
ing the silver stained S100 protein spots, paired with the
1D-western blot image on the same tissue extract.
Association of S100 members with tumor variables
The expression levels of S100 proteins were correlated
with current clinical-pathological parameters which
included age, tumor size, nodal status, immuno-cyto-
chemical presence of HER-2, oestrogen receptors, pro-
gesterone receptor, and Ki67 (Table 2). The results
showed no significant correlations of the different S100
protein forms with tumor variables, except for S100A6
(isoform b) and S100A13 correlating with Ki67 (p =
Table 1 Synopsis of the information on the identified S100 proteins
SPOT
NUMBER
ENTRY
NAME
SPOT
NAME
AC PROTEIN
NAME
MOWSE
SCORE
NUMBER OF MASS
VALUES SEARCHED
NUMBER OF MASS
VALUES MATCHED
(%)
SEQUENCE
COVERAGE
THEORETICAL
MW (Da) - pI
1 S10A2 S100A2 P29034 S100-A2 229 18 16 59 11337-4.68
7 S10A4 S100A4 P26447 S100-A4
Metastasin
129 16 10 51 11949-5.85
2 S10A6 S100A6 a P06703 S100-A6
Calcyclin
77 4 4 28 10230-5.33
4 S10A6 S100A6
b
P06703 S100-A6
Calcyclin
68 5 4 40 10230-5.33
8 S10A7 S100A7 a P31151 S100-A7
Psoriasin
80 8 5 39 11470-6.27
10 S10A7 S100A7
b
P31151 S100-A7
Psoriasin
101 6 6 35 11470-6.27
11 S10A8 S100A8 P05109 S100-A8
Calgranulin
76 36 8 49 10885-6.51
3 S10AB S100A11
a
P31949 S100-A11
Calgizzarin
82 5 5 42 11847-6.56
5 S10AB S100A11
b
P31949 S100-A11
Calgizzarin
127 11 11 61 11847-6.56
9 S10AB S100A11
c
P31949 S100-A11
Calgizzarin
73 6 5 34 11847-6.56
6 S10AD S100A13 Q99584 S100-A13 226 19 13 89 11464-5.91
Entry names, protein names, accession numbers and theoretical MW and pI are from the Swiss-Prot database. Mowse score represent -10* Log (P), where P ist h e
probability that the observed match is a random event. Number of mass value matched and the % of sequence coverage are given by Mascot database in the
protein view session.
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ing with nodal status (p = 0.021).
Association of S100 members with metastases
From several reports, individual S100 proteins have been
found to correlate with metastasis; however a wide-
ranging pattern of S100 protein members in a large
scale of breast cancer patients was never screened
before. Therefore, we analyzed our data set concerning
the expression level of S100 proteins with respect to
their association with the development of distant metas-
tases. Patients with 3-year follow-up were fifty seven, 22
had developed distant metastases while 35 were disease-
free. As shown in Fig. 10 the expression level of each
S100 protein (expressed as average among patients of
each group) was 1.07 to 2.13 fold higher in the
Figure 4 Panel of cropped areas of individual S100 protein spots from matched breast cancer tissues (BCT) and non tumoral adjacent
tissues (NAT). The experiments were conducted on a pilot group of 10 patients, selected for the present study.
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was used to detect expression variance among the S100
proteins in metastatic patients compared with the dis-
ease free group.
Discussion
The clinical interest for S100 proteins as putative cancer
biomarkers is continuously expanding. Major reasons
for this are their multifunctional properties with a regu-
latory role in a variety of cellular and extracellular pro-
cesses, and also the clustering of the majority of the
S100 genes on a region of chromosome 1q21 which are
often rearranged in cancer.
Although there are numerous reports on the correla-
tion or involvement of individual S100 members in can-
cer [25-29], to our knowledge this study is the first to
screen contextually for several members of the protein
family through a large-scale proteomic approach. Pro-
teomics is presently the only system able to detect pro-
tein isoforms of potential interest, which are not
detectable by gene expression or immunohistochemical
investigations [30-34]. Collectively we have identified
eleven S100 protein forms, corresponding to 7 protein
members. The first goal of this study was the finding of
the almost exclusive expression of S100 members in
cancerous breast tissues compared with normal adjacent
tissues, an observation that per se substantiates the role
of S100 proteins as putative biomarkers. This observa-
tion is in good agreement with literature data support-
ing the evidence that altered expression of many of
S100 members occurs in several cancers including
breast, lung, kidney, bladder, gastric, thyroid, prostate
and oral cancers [see for review [29]].
The second goal of our study was the quali-quantitative
proteomic screening of a significant number of the S100
family proteins among a large group of 100 breast cancer
patients, all diagnosed as ductal infiltrating carcinomas.
Figure 5 Quantitative analysis of S100 proteins, given as box-
plot graphs, of matched breast cancer tissues (BCT) and non
tumoral adjacent tissues (NAT). Quantification was deduced by
the 2 D gels, analyzed by Image-Master software. In ordinate are the
values of N%V. Statistical significance was analyzed by the Student’s
t-test: *p < 0.05 was considered significant; **p < 0.01 highly
significant; ***p < 0.001 very highly significant. The data in the
graphs are expressed as median ±SD.
Figure 6 Qualitative analysis of the eleven S100 protein forms
among the 100 patients. (A) Diagram illustrating the occurrence
of the identified S100 protein members (abscissa) among the
patients indicated from P01 to P100 (ordinate). The gray boxes
indicate absence of proteins in the map of the corresponding
patient; the crosses in the white boxes indicate the patients
expressing the given protein at its highest level among the others.
(B) Table reporting the percentage of the enrolled patients
expressing the different S100 protein forms.
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members are ubiquitously expressed in all patients while
others appeared more sporadic. Among the first, are:
S100A2, S100A6, S100A11 and S100A13 (all isoforms,
when present); the members with more or less sporadic
appearance are: S100A8 (71%), S100A4 (57%) and
S100A7 (51%, isoform a and 63%, isoform b).
The quantitative evaluation showed that the expres-
sion levels of each S100 member was different among
patients, but collectively, most of the S100 protein
forms were statistically correlated. This adds complexity
to the role of this protein category in breast cancer and
suggests a possible common pathway of (dys-)
regulation.
Finally, we investigated the prognostic potential of
S100 proteins to predict distant metastatic relapse dur-
ing a time lapse of three years from the surgical inter-
vention. The most robust correlation with metastasis
regarded primarily the protein S100A4, and secondly
the protein S100A7. The S100A4, also named metastasin
for its presumed role in metastasis promotion, is one of
the most investigated in the recent literature [see for
review [35]], as a promising biomarker of breast metas-
tasis. Our results are in agreement with this hypothesis,
since S100A4 expression level shows an increase of
more than 2 fold in the metastatic group.
Figure 7 Diagram of the relative intensities of the eleven S100
protein forms among the 100 patients. In abscissa are indicated
the protein names and in the ordinate the density values. Bars
indicate the mean of each protein expression level among patients.
Figure 8 Association analysis of expression levels of S100 members evaluated as N%V. Statistical significance of the S100 members
correlation was assessed by Pearson test and considered as significant, highly significant and very highly significant (*p < 0.05; **p < 0.01; ***p
< 0.001). Correlation is indicated as Yes.
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Present data strongly support the hypothesis that a sig-
nificant deregulation of multiple S100 family members
is associated with breast cancer progression, and suggest
that these proteins might act as potential prognostic
factors for patient stratification. Although the patho-
Figure 9 Western Blot validation of S100 proteins detected by
silver stain proteomics. The panel shows the cropped areas of 2
D gels containing the silver stained S100 protein spots (left), paired
with the 1D-western blot image on the same selected breast cancer
tissue (right). The validation was performed on two surgical samples
for each S100-antibody, chosen among the 100 patient tissues
showing respectively high and low levels of each S100 protein.
Table 2 Clinical-pathological characteristics of patients and correlation with S100 protein expression
S100A2 S100A4 S100A6
a
S100A6 b S100A7
a
S100A7
b
S100A8 S100A11
a
S100A11
b
S100A11
c
S100A13
Age (n = 100) p > 0.05 p > 0.05 p > 0.05 p > 0.05 p > 0.05 p > 0.05 p > 0.05 p > 0.05 p > 0.05 p > 0.05 p > 0.05
≤ 56 42%
>5 6 58%
T (n = 73) p > 0.05 p > 0.05 p > 0.05 p > 0.05 p > 0.05 p > 0.05 p > 0.05 p > 0.05 p > 0.05 p > 0.05 p > 0.05
1 33%
2 56%
3 5%
4 6%
N (n = 76) p > 0.05 p > 0.05 p > 0.05 p > 0.05 p > 0.05 p > 0.05 p > 0.05 p=
0.0210*
p > 0.05 p > 0.05 p > 0.05
Neg 39%
Pos 61%
HER-2 (n = 80) p > 0.05 p > 0.05 p > 0.05 p > 0.05 p > 0.05 p > 0.05 p > 0.05 p > 0.05 p > 0.05 p > 0.05 p > 0.05
0 45%
1 24%
2 14%
3 17%
ER (n = 90) p > 0.05 p > 0.05 p > 0.05 p > 0.05 p > 0.05 p > 0.05 p > 0.05 p > 0.05 p > 0.05 p > 0.05 p > 0.05
Neg 31%
Pos 69%
PR (n = 89) p > 0.05 p > 0.05 p > 0.05 p > 0.05 p > 0.05 p > 0.05 p > 0.05 p > 0.05 p > 0.05 p > 0.05 p > 0.05
Neg 42%
Pos 58%
Ki67% (n = 77) p > 0.05 p > 0.05 p > 0.05 p = 0.043* p > 0.05 p > 0.05 p > 0.05 p > 0.05 p > 0.05 p > 0.05 p=
0.041*
≤ 15% 23%
16-30% 29%
> 30% 48%
Pearson t-test was used to evaluate the association among age, T, N, HER-2, ER, PR and Ki67 and S100 proteins expression. *p < 0.05 was considered significant
and marked in bold.
Figure 10 Changes in S100 expression levels between
metastases and disease free -related patients. Data are
represented as ratio of metastatic group to disease free group.
P-values, calculated by F-test were considered as significant, highly
significant and very highly significant (*p < 0.05; **p < 0.01;
***p < 0.001).
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still require further clarification, the description of their
differential occurrence in a large group of breast cancer
patients, at proteomic levels, is a further important step
promoting advancement of scientific knowledge for bio-
marker application in clinical practice.
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